Khoriah Indrihutami, Krisin Chand, Rizka Fahmia, Mutia Rahardjani, Fitria Wulandari, Decy Subekti, Rintis Noviyanti, Amin Soebandrio, Noch T Mallisa, I Made Mardika, Waras Budiman, Irwan Suriswan, Yogi Ertanto, Mei-Chun Chen, Tooba Murshedkar, Yonas Abebe, B Kim Lee Sim, Stephen L Hoffman, Thomas L Richie, Sky Chen, Iqbal R F Elyazar, Lenny L Ekawati, J Kevin Baird, Erni J Nelwan
Malaria eradication efforts prioritize safe and efficient vaccination strategies, although none with high-level efficacy against malaria infection are yet available. Among several vaccine candidates, Sanaria® PfSPZ Vaccine and Sanaria PfSPZ-CVac are, respectively, live radiation- and chemo-attenuated sporozoite vaccines designed to prevent infection with Plasmodium falciparum, the leading cause of malaria-related morbidity and mortality. We are conducting a randomized normal saline placebo-controlled trial called IDSPZV1 that will analyze the safety, tolerability, immunogenicity, and efficacy of PfSPZ Vaccine and PfSPZ-CVac administered pre-deployment to malaria-naive Indonesian soldiers assigned to temporary duties in a high malaria transmission area...
March 26, 2024: American Journal of Tropical Medicine and Hygiene